Krystal Biotech, Inc. $KRYS Shares Purchased by Principal Financial Group Inc.

Principal Financial Group Inc. increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 15.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 165,074 shares of the company’s stock after acquiring an additional 22,231 shares during the period. Principal Financial Group Inc.’s holdings in Krystal Biotech were worth $40,697,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in KRYS. Bessemer Group Inc. increased its stake in shares of Krystal Biotech by 106.9% during the third quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock valued at $26,000 after acquiring an additional 77 shares during the period. Sound Income Strategies LLC increased its stake in shares of Krystal Biotech by 1,270.0% during the fourth quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock valued at $34,000 after acquiring an additional 127 shares during the period. Danske Bank A S acquired a new stake in Krystal Biotech during the third quarter valued at approximately $35,000. MAI Capital Management lifted its stake in Krystal Biotech by 79.7% during the third quarter. MAI Capital Management now owns 284 shares of the company’s stock valued at $50,000 after purchasing an additional 126 shares during the last quarter. Finally, Hantz Financial Services Inc. lifted its stake in Krystal Biotech by 61.3% during the third quarter. Hantz Financial Services Inc. now owns 292 shares of the company’s stock valued at $52,000 after purchasing an additional 111 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on KRYS. Guggenheim increased their target price on shares of Krystal Biotech from $224.00 to $284.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Evercore reissued an “outperform” rating and set a $300.00 target price on shares of Krystal Biotech in a research note on Tuesday. Citigroup increased their target price on shares of Krystal Biotech from $371.00 to $378.00 and gave the company a “buy” rating in a research note on Tuesday. Wolfe Research began coverage on shares of Krystal Biotech in a research note on Friday, March 27th. They set a “peer perform” rating for the company. Finally, The Goldman Sachs Group increased their target price on shares of Krystal Biotech from $206.00 to $327.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Ten analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Krystal Biotech has a consensus rating of “Moderate Buy” and an average target price of $324.11.

Krystal Biotech Stock Performance

Krystal Biotech stock opened at $305.71 on Friday. The firm has a market cap of $9.01 billion, a PE ratio of 40.87 and a beta of 0.50. The firm’s 50 day moving average price is $263.06 and its two-hundred day moving average price is $248.61. Krystal Biotech, Inc. has a twelve month low of $122.80 and a twelve month high of $306.10.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, beating the consensus estimate of $1.45 by $0.38. The business had revenue of $116.36 million during the quarter, compared to analysts’ expectations of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. Equities analysts anticipate that Krystal Biotech, Inc. will post 7.98 EPS for the current fiscal year.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $263.21, for a total value of $6,580,250.00. Following the completion of the sale, the insider directly owned 1,403,155 shares of the company’s stock, valued at $369,324,427.55. The trade was a 1.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $267.60, for a total transaction of $200,700.00. Following the completion of the sale, the chief accounting officer directly owned 22,366 shares of the company’s stock, valued at $5,985,141.60. This represents a 3.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 129,164 shares of company stock valued at $34,538,578. 13.10% of the stock is currently owned by insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.